
Eli Lilly and Company LLY
Quarterly report 2025-Q2
added 08-07-2025
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
901 M |
Market Cap[1] |
$ 968 B |
EBITDA (LTM) |
$ 2.37 B |
P/E (LTM) |
78.22 |
P/S (LTM) |
18.97 |
EPS (LTM) |
13.74 |
Eli Lilly and Company is one of the world's largest pharmaceutical companies, specializing in the development, manufacturing, and sale of innovative drugs for the treatment of various diseases.
The company was founded in 1876 in Indianapolis, Indiana and has since become a leader in the pharmaceutical industry. Eli Lilly and Company develops and manufactures a wide range of drugs, including those for diabetes, cancer, mental disorders, Alzheimer's disease, and other illnesses.
One of the company's most well-known developments is insulin, which was created in 1923. This drug became the first effective treatment for diabetes and has saved millions of lives worldwide.
Eli Lilly and Company actively invests in research and development of new drugs to help patients worldwide fight various diseases. The company also aims to improve the quality of life for patients by providing them with access to high-quality drugs. Is a global company with operations in more than 125 countries. The company cares about its employees and society as a whole, participating in various charitable projects and social responsibility programs.
Overall, is one of the most successful and innovative companies in the pharmaceutical industry. Its products help millions of people worldwide overcome difficulties associated with various diseases and improve their quality of life.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | ||
|
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | ||
|
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market | ||
|
Aclaris Therapeutics
ACRS
|
$ 3.01 | 3.79 % | $ 233 M | Nasdaq Global Select Market | ||
|
Alterity Therapeutics Limited
ATHE
|
$ 3.08 | 0.65 % | $ 7.41 B | Nasdaq Capital Market | ||
|
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Alpine Immune Sciences
ALPN
|
- | - | $ 2.17 B | Nasdaq Global Market | ||
|
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | ||
|
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | ||
|
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | ||
|
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | ||
|
Avenue Therapeutics
ATXI
|
- | -52.27 % | $ 4.45 M | Nasdaq Global Select Market | ||
|
Autolus Therapeutics plc
AUTL
|
$ 1.99 | 1.02 % | $ 508 M | Nasdaq Global Select Market | ||
|
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | ||
|
Ascendis Pharma A/S
ASND
|
$ 213.24 | 1.87 % | $ 5 B | Nasdaq Global Select Market | ||
|
BioDelivery Sciences International
BDSI
|
- | -4.8 % | $ 255 M | Nasdaq Global Select Market | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 11.29 | -3.01 % | $ 730 M | NYSE | ||
|
BioVie
BIVI
|
$ 1.16 | 2.65 % | $ 1.71 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX | ||
|
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | ||
|
Berkeley Lights
BLI
|
- | -7.31 % | $ 87 M | Nasdaq Global Select Market | ||
|
ARCA biopharma
ABIO
|
- | 1052.0 % | $ 415 M | Nasdaq Capital Market | ||
|
Acasti Pharma
ACST
|
- | 4.01 % | $ 150 M | Nasdaq Capital Market | ||
|
Adaptimmune Therapeutics plc
ADAP
|
- | -15.15 % | $ 60.3 M | Nasdaq Global Select Market | ||
|
bluebird bio
BLUE
|
- | - | $ 546 M | Nasdaq Global Select Market,SPB | ||
|
Albireo Pharma
ALBO
|
- | -0.23 % | $ 916 M | Nasdaq Capital Market | ||
|
BioNTech SE
BNTX
|
$ 95.2 | -0.08 % | $ 27.2 B | Nasdaq Global Select Market | ||
|
Can-Fite BioPharma Ltd.
CANF
|
$ 0.2 | 8.46 % | $ 435 M | NYSE American | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 26.78 | -0.81 % | $ 1.3 B | Nasdaq Global Select Market | ||
|
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market | ||
|
Anika Therapeutics
ANIK
|
$ 9.61 | 0.63 % | $ 141 M | Nasdaq Global Select Market,SPB | ||
|
Catalyst Biosciences
CBIO
|
$ 11.86 | 2.24 % | $ 781 M | Nasdaq Capital Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Acer Therapeutics
ACER
|
- | 2.71 % | $ 14 M | Nasdaq Capital Market | ||
|
Certara
CERT
|
$ 8.81 | -0.56 % | $ 1.41 B | Nasdaq Global Select Market | ||
|
Axon Enterprise
AXON
|
$ 567.93 | -0.73 % | $ 43 B | Nasdaq Global Select Market,SPB | ||
|
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market | ||
|
Aytu BioScience
AYTU
|
$ 2.6 | 1.96 % | $ 16.3 M | Nasdaq Capital Market | ||
|
AstraZeneca PLC
AZN
|
$ 91.93 | -0.63 % | $ 96.9 B | Nasdaq Global Select Market | ||
|
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Brickell Biotech
BBI
|
- | -5.38 % | $ 6.06 M | Nasdaq Capital Market | ||
|
Celldex Therapeutics
CLDX
|
$ 27.16 | 2.76 % | $ 1.75 M | Nasdaq Global Select Market | ||
|
Burford Capital Limited
BUR
|
$ 8.92 | -1.0 % | $ 1.46 B | NYSE | ||
|
Cellectis S.A.
CLLS
|
$ 4.84 | 1.26 % | $ 116 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.